ReviewInternational journal of nanomedicine2026
Nanoparticle-Mediated Lutein Delivery for Diabetic Retinopathy: From Blood-Retinal Barrier Crossing to Neurovascular Unit Protection.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR) is increasingly understood as an integrated neurovascular unit (NVU) pathology driven by chronic hyperglycemia, rather than solely a microvascular complication. Anti-vascular endothelial growth factor (anti-VEGF) therapy remains limited by repeated intravitreal injections, treatment resistance, and failure to reverse early neurodegeneration. Lutein, a natural carotenoid, may counter these refractory dimensions by activating the nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant pathway and suppressing neuroinflammation across NVU components. However, its poor aqueous solubility, chemical instability, and restricted blood-retinal barrier (BRB) permeation limit retinal bioavailability and clinical translation. Nanoscale targeted delivery can improve lutein solubility and stability and enable trans-BRB transport via the enhanced permeability and retention effect or receptor-mediated transcytosis, thereby enhancing precise NVU protection. This review integrates lutein's mechanisms against DR-related NVU injury, design strategies for nanoscale delivery systems and trans-BRB transport, and preclinical efficacy with translational bottlenecks, to support advancement of lutein from dietary supplement to precision adjuvant therapy for DR. Unlike reviews treating lutein as an isolated nutraceutical or materials target, it connects nanomaterial engineering with clinical translation and regulatory science. Preclinical studies show that nanoformulated lutein improves oral bioavailability, retinal accumulation, and oxidative/inflammatory injury in diabetic models. Translation remains hindered by limited long-term safety data, scalable manufacturing, and unclear regulatory classification. Future priorities include stage-adaptive nanoplatforms, standardized preclinical evaluation, and rigorously designed multicenter clinical trials to establish efficacy, safety, and regulatory readiness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.